News Article | April 12, 2017
MADISON, Wis., April 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend, II, M.D. as vice president and chief medical officer effective April 17, 2017. “Cellectar has accelerated and expanded its research and development program to include multiple clinical trials for our lead product candidate CLR 131, as well as the active preclinical development of additional compounds utilizing our PDC platform,” said Jim Caruso, president and CEO of Cellectar Biosciences. “John’s depth of drug development experience in the biopharmaceutical industry, specifically, advancing drugs from preclinical stage through clinical studies, as well as successful oversight of the regulatory process, precisely meets our current need in helming our PDC programs and we look forward to benefitting from his leadership.” Dr. Friend, age 47, brings 15 years of global drug development expertise and general management experience in oncology, inflammation, endocrine/metabolism, and pain management to Cellectar. Prior to joining the company, John spent more than seven years at Helsinn Therapeutics leading its research and development division. Most recently he served as senior vice president of Medical and Scientific Affairs at Helsinn, building the non-clinical, clinical, medical and regulatory affairs teams to lead multiple global franchises from early product development to market commercialization. Prior to his time at Helsinn, Dr. Friend held executive responsibility for clinical research, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies including Akros Pharma, Actavis, Alpharma, Hospira and Abbott. After obtaining an undergraduate degree in Chemistry from Southern Methodist University, John earned his medical degree from UMDNJ-Robert Wood Johnson Medical School (now Rutgers, RWJMS). He completed post-graduate residency program in family medicine and subsequently served as clinical director and faculty attending physician at Cabarrus Family Medicine Residency Program in North Carolina. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer-targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma, as well as a Phase II clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical-stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com. This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
News Article | November 18, 2016
Marvell Scott, M.D., Discusses Treatment of Professional Athletes Using Injections That Do Not Have the Risks Associated with Steroids, Opioids, or NSAIDs. Marvell Scott, M.D., conducted a webinar about alternative pain relief treatments on October 12, 2016, which was watched by doctors from coast to coast. The event is now available to watch online HERE In the webinar, Dr. Scott discusses how he treats several musculoskeletal conditions including orthopedic surgery recovery, tennis elbow, tendonitis, tendinopathy, partial tears, post-surgical and post-traumatic arthrofibrosis, sports injuries, musculoskeletal pain, and osteoarthritis. Dr. Scott’s practice includes a wide range of patients, from some of the greatest athletes in the world to older patients dealing with high levels of disability due to intractable pain. Dr. Scott began his practice exclusively using a wide range of conventional drugs like glucocorticoid injections, but has since broadened his range of medications to include the use of natural medications, where they have proven to be effective. Today MediNatura™ injections and topical medicines are a mainstay of the alternative side of Dr. Scott’s practice. “In my practice, we have seen that the risks with Traumeel®, Zeel®, and other MediNatura™ injections are minimal in comparison with traditional glucocorticoid injections, but the benefits for pain relief are comparable,” said Dr. Scott. Many of his patients have endured exhaustive attempts to alleviate their pain through conventional treatment options, including multiple cortisone injections. “Cortisone is your synthetic version of cortisol, which is your aging hormone, so there are a lot of limitations with frequency and dosage,” said Dr. Scott. “With MediNatura™ products like Traumeel®, Zeel®, Neuralgo-Rheum®, and other injections I am able to inject a much broader spectrum of areas without weakening the tendon or suppressing the immune system.” “I treat well over 100 patients a week. Twenty to thirty injections a day, sometimes seven days a week. This may be tens of thousands of injections, and I haven’t had any real adverse reactions,” said Dr. Scott. In the webinar, Dr. Scott mentions that his professional athlete clients needed reassurance that Traumeel® and Zeel® contain no performance-enhancing drugs (PEDs). To address this concern, Dr. Scott independently hired a prestigious U.S. laboratory to conduct testing, which confirmed that the treatments are free of banned substances, including PEDs. Additionally, Traumeel® and Zeel® have never caused an issue with the random drug screening tests conducted on professional athletes. Dr. Scott completed his internal medicine residency at Mount Sinai School of Medicine’s sister hospital Cabrini Medical Center. He did his sports medicine specialty fellowship at UMDNJ-Robert Wood Johnson Medical School, where he worked with Rutgers and Princeton’s 30 varsity sports teams. Almost eight years ago, while working in northern Italy with the EuroLeague (a professional basketball league) and with the international soccer team A.C. Milan, he was introduced to the MediNatura™ products. He also learned that the doctors who treat the German Olympic team, German national soccer team, and multiple professional soccer teams such as Real Madrid and Bayern Munich, were successfully using Traumeel®. MediNatura™ Inc., a Delaware Corporation headquartered in greater Philadelphia, specializes in prescription and over the counter pharmaceuticals made from natural medicines. You can reach MediNatura™ toll-free at 1-844-633-4628 Monday through Friday from 8 a.m. to 5 p.m. MST or visit MediNatura.com MediNatura™ imports Traumeel®, Zeel®, and other injections from Germany, where they are manufactured in FDA-audited factories according to strict U.S. pharmaceutical standards for purity and sterility. Full prescribing information for Traumeel® is available at CLICK HERE and for Zeel® at CLICK HERE.
Mehta R.,UMDNJ |
Journal of Perinatology | Year: 2011
Objective: The aim of this study was to identify the independent effect of very preterm gestation on breast milk content of biologically active proteins (secretory immunoglobulin A (sIgA), lysozyme, lactoferrin, osteoprotegerin (OPG), leptin, adiponectin and β-endorphin (b-EP)) during the first month of lactation.Study Design: We collected samples of transitional (6 to 8 and 13 to 15 days) and mature (20 to 22 and 27 to 29 days) milk from mothers after term (38 to 41 weeks) or very preterm (24 to 31 weeks) delivery. The levels of sIgA, lysozyme, lactoferrin, OPG, leptin, adiponectin and b-EP in the breast milk were quantified using enzyme-linked immunosorbent assay or enzyme immunoassay kits. Statistical analysis included descriptive statistics and regression analysis. Result: Sixty breast milk samples were collected from 15 mothers after very preterm (preterm breast milk, PBM) and 20 samples from 5 mothers after term (term breast milk, TBM) deliveries. Decrease in lysozyme, lactoferrin, OPG, leptin, adiponectin and b-EP but no change in sIgA was recorded during the first month of lactation in both TBM and PBM. The IgA, lysozyme and adiponectin were higher in PBM than in TBM, whereas concentrations of lactoferrin, OPG and leptin were higher in TBM than in PBM (P<0.05 to 0.0001). A similar pattern was seen in the lysozyme, leptin and adiponectin concentration in mature milk. Increased b-EP levels in breast milk were associated with the vaginal mode of delivery but not gestational age. Conclusion: Although a similar pattern of change was observed in the breast milk bioactive proteins during the first month of lactation after term and very preterm gestation, PBM is a better source of factors with antibacterial/anti-inflammatory activities but is constantly deficient in leptin, which is involved in neuroendocrine regulation. © 2011 Nature America, Inc. All rights reserved.
Matise M.P.,UMDNJ |
Current Topics in Developmental Biology | Year: 2011
Sonic Hedgehog (Shh) is one of three mammalian orthologs of the Hedgehog (Hh) family of secreted proteins first identified for their role in patterning the Drosophila embryo. In this review, we will highlight some of the outstanding questions regarding how Shh signaling controls embryonic development. We will mainly consider its role in the developing mammalian central nervous system (CNS) where the pathway plays a critical role in orchestrating the specification of distinct cell fates within ventral regions, a process of exquisite complexity that is necessary for the proper wiring and hence function of the mature system. Embryonic development is a process that plays out in both the spatial and the temporal dimensions, and it is becoming increasingly clear that our understanding of Shh signaling in the CNS is grounded in an appreciation for the dynamic nature of this process. In addition, any consideration of Hh signaling must by necessity include a consideration of data from many different model organisms and systems. In many cases, the extent to which insights gained from these studies are applicable to the CNS remains to be determined, yet they provide a strong framework in which to explore its role in CNS development. We will also discuss how Shh controls cell fate diversification through the regulation of patterned target gene expression in the spinal cord, a region where our understanding of the morphogenetic action of graded Shh signaling is perhaps the furthest advanced. © 2011 Elsevier Inc.
Balashov K.E.,UMDNJ |
Lindzen E.,State University of New York at Buffalo
Multiple Sclerosis Journal | Year: 2012
Background and objectives: It is widely accepted that typical acute demyelinating lesions in relapsingremitting multiple sclerosis (RRMS) exhibit vasogenic edema with increased diffusion, as demonstrated by an increased apparent diffusion coefficient on MRI. In contrast, acute ischemic lesions demonstrate cytotoxic edema with restricted diffusion. Recent reports have documented selected cases of acute demyelinating lesions exhibiting restricted diffusion (ADLRD) in MS. We aimed to assess the morphologies, distributions, signal characteristics and changes over time of nine ADLRD. An additional goal was to obtain clinical correlations and relate our findings to all previously published case reports describing ADLRD. Methods: A retrospective case series study was performed at two academic centers. MRI characteristics of nine ADLRD found in six RRMS patients were compared with typical active symptomatic contrast-enhancing lesions with increased or normal diffusion in control RRMS patients. Results: The average size of ADLRD was not significantly different from typical lesions. A periventricular location and faint signal on T2-weighted images were significantly more common for ADLRD compared with typical lesions. Two patients with ADLRD on initial MRI exhibited new ADLRD on their follow up scans. Conclusion: Our results and review of prior published cases suggest that ADLRD represent a new variant of MS lesion. The restricted diffusion that is a characteristic of ADLRD on MRI is a new challenge in the differential diagnosis of stroke in young adults. The pathogenesis of ADLRD remains to be understood. © The Author(s) 2012.
Annals of the New York Academy of Sciences | Year: 2010
Age-associated decrease in nitric oxide (NO) production may be related to an increase in cardiovascular events, sexual dysfunction, and osteoporosis. Relative NO deficiency is a plausible biological basis for NO replacement therapy. Hormone replacement therapy (HRT) enhances local NO production and rectifies NO deficiency in postmenopausal women. However, excess local production of NO aggravates bone destruction in inflammatory arthropathies. In addition to its use in alleviating angina and erectile dysfunction, NO compounds could be a valuable supplemental therapy for chronic conditions including osteoporosis. Estrogen mediates its beneficial effects in bone, in part via the NO/cGMP pathway; hence NO donor therapy is an alternative to estrogen, estrogen agonists-antagonists, and androgen receptor modulator therapy in the prevention and treatment of osteoporosis. Large numbers of animal studies and human pilot studies support the concept of using NO donors for preventing bone loss. Administration of exogenous NO or prolonging endogenous NO activity are practical ways to supplement NO. © 2010 New York Academy of Sciences.
Fitzgerald-Bocarsly P.,UMDNJ |
Fitzgerald-Bocarsly P.,Rutgers University |
Jacobs E.S.,Rutgers University
Journal of Leukocyte Biology | Year: 2010
pDC are the most potent IFN-α-producing cells in the body and serve as a vital link between innate and adaptive immunity. Deficiencies in pDC function were among the earliest observations of immune dysfunction in HIV-1 infection. Herein, we review the status of pDC in individuals with HIV-1 infection and the potential role of these cells in pathogenesis. We begin by reviewing the basic properties of pDC and then discuss the compromise in circulating pDC numbers and function in early and viremic HIV-1 infection and mechanisms that might account for their depletion in HIV-infected patients. In addition, we review the evidence that chronic production of IFN-α, probably through the chronic activation of pDC, is central to the immune activation that is so detrimental in HIV infection. Finally, we discuss the importance of balance in pDC numbers and function and the potential value of using absolute pDC counts and function as a biomarker, along with CD4 + cell counts and VL in HIV-1-infected patients. © Society for Leukocyte Biology.
Journal of Clinical Gastroenterology | Year: 2012
Sjogren syndrome (SS) is an autoimmune disease that affects exocrine glands and therefore may affect the gastrointestinal system, from the mouth, esophagus, and bowel to the liver and pancreas. Oral involvement in SS is mainly characterized by dryness, with a wide spectrum of symptoms, from mild-to-severe xerostomia with dysgeusia and tooth decay. The dysphagia, although common, does not correlate with the reduced salivary flow rate or the dysmotility that may be present. Dyspepsia, found in up to 23% of patients, may be associated with gastritis, reduced acid production, and antiparietal cell antibodies, but rarely pernicious anemia. Pancreatic involvement, although rare, includes pancreatitis and pancreatic insufficiency. The most common causes of liver disease are primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic fatty liver disease, and hepatitis C virus (HCV). Although abnormal liver tests are found in up to 49% of patients, they are usually mild. Although sicca syndrome, abnormal histology of the salivary glands, and abnormal sialograms are common in primary biliary cirrhosis, the antibodies to Ro/SSA or La/SSB antigens are infrequent. Xerostomia, sialadenitis, abnormal salivary flow rates, and abnormal Schirmer test in HCV vary widely among the studies, although the antibodies to Ro/SSA or La/SSB are only 1%. Several studies show that HCV is in saliva, although how this may impact sicca syndrome or SS in HCV is unclear. SS as a disease of exocrine glands affects many parts of the gastrointestinal system. Copyright © 2012 by Lippincott Williams & Wilkins.
Journal of neurointerventional surgery | Year: 2010
Ruptured intracranial aneurysms are responsible for over 90% of cases of spontaneous subarachnoid hemorrhage (SAH). Conventional digital subtraction angiography (DSA) remains the gold standard for diagnosing the source of SAH. A prospective study is presented wherein SAH patients underwent three dimensional CT angiography (CTA) prior to DSA in order to assess the specificity and sensitivity of this non-invasive modality to detect aneurysms. 179 consecutive patients with spontaneous SAH presented over 36 months, as identified by screening CT and CTA. Patients with negative CTA findings underwent DSA within 24 h of presentation. All patients who were determined to have angiographically negative SAH underwent follow-up DSA 2 weeks later. Of the 179 patients screened by CTA, 13 (7%) were negative for aneurysms or other vascular lesions (arteriovenous malformation or dural fistula) on CTA and underwent DSA. No new lesions were identified on six vessel angiography, resulting in a 0% false negative rate (sensitivity 100%, predictive value 100%). MRI to rule out thrombosed aneurysms and repeat angiography at the 2 week follow-up were negative. Sensitivity and specificity were higher than previously reported, suggesting that CTA may be used as an initial screening tool in lieu of DSA. Further studies are necessary to determine if CTA can supplant DSA in ruling out all forms of vascular disease in idiopathic SAH.
Methods in Molecular Biology | Year: 2013
The excised inside-out patch clamp technique gives rapid access to the intracellular surface of the plasma membrane while measuring channel activity. This way the effects of intracellular regulators of ion channels or transporters can be studied in isolation, in the absence of most of the cellular machinery. This chapter summarizes our experience with this technique using large patches to study various ion channels expressed in Xenopus oocytes. © 2013 Springer Science+Business Media, LLC.